COMP <GO>
BRKR vs UNH // REVENUE GROWTH (YOY)
Bruker Corporation (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: BRKR 1
— UNH 13
▲ REVENUE GROWTH (YOY) LEADER: UNH
LAST: $55.69 (-2.42%) • MKT CAP: $8.48B
revenue-growth
2.10%
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
revenue-growth
3.33%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BRKR VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BRKR | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 45.90% | 88.31% | -42.41 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 1.30% | 12.38% | -11.08 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 75.7x | 15.3x | +60.43 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 0.46% | 6.25% | -5.79 | UNH | /fcf-yield <GO> |
| Operating Margin | 2.00% | 5.32% | -3.32 | UNH | /operating-margins <GO> |
| Net Profit Margin | -0.20% | 3.53% | -3.73 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 2.10% | 3.33% | -1.23 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.24% | 2.29% | -2.05 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.81 | 3.09 | -0.28 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.4 | 55.1 | -11.70 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.97 | 0.33 | +0.64 | BRKR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 17.7x | +4.26 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.48B | $359.43B | -$350.95B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BRKR REV | UNH REV | BRKR GROSS % | UNH GROSS % | BRKR FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.44B | $447.57B | 45.9% | 88.7% | $43.3M | $16.07B |
| FY 2024 | $3.37B | $400.28B | 49.0% | 88.3% | $136.0M | $20.70B |
| FY 2023 | $2.96B | $371.62B | — | 89.6% | $216.7M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BRKR // BETA 0.97
UNH // BETA 0.33